Brenneman Douglas E
Johnson and Johnson Pharmaceutical Research and Development, Welsh & McKean Roads, Spring House, PA 19477, USA.
Peptides. 2007 Sep;28(9):1720-6. doi: 10.1016/j.peptides.2007.04.002. Epub 2007 Apr 19.
The neuroprotective properties of vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP) place these peptides in a special category of ligands that have implications for our understanding of pathological conditions as well as a potential basis for therapeutic intervention. It is remarkable that these peptides have a protective impact against such a wide variety of clinical relevant toxic substances. This protective diversity is consistent with the multiple pathways that are activated or inhibited by the action of these peptides. Although knowledge is emerging on the neuroprotective mechanisms of VIP and PACAP, it is already evident that these two peptides are not identical in their action and each peptide has multiple mechanisms that allow for neuroprotective diversity. The multiple intracellular signaling pathways and differing extracellular mediators of neuroprotection contribute to this diversity of action. In this review, examples of neuroprotective actions will be presented that serve to demonstrate the remarkable breadth of neuroprotective processes produced by VIP and PACAP.
血管活性肠肽（VIP）和垂体腺苷酸环化酶激活肽（PACAP）的神经保护特性，使这些肽类属于一类特殊的配体，这对于我们理解病理状况具有重要意义，同时也是治疗干预的潜在基础。值得注意的是，这些肽对多种临床相关的有毒物质具有保护作用。这种保护的多样性与这些肽作用所激活或抑制的多种途径是一致的。尽管关于VIP和PACAP神经保护机制的知识正在不断涌现，但很明显这两种肽的作用并不相同，且每种肽都有多种机制实现神经保护的多样性。神经保护的多种细胞内信号通路和不同的细胞外介质促成了这种作用的多样性。在这篇综述中，将展示神经保护作用的实例，以证明VIP和PACAP所产生的神经保护过程具有显著的广度。
